试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-03-18
A Study to Assess the Safety, Pharmacodynamics, and Immunogenicity of PXVX0047
编号:NCT03160339登记状态:提前终止企业 / 申办者:Emergent BioSolutions
药物 / 成分:PXVX0047 Vaccine、Teva Ad4/Ad7 Vaccine
登记的停止原因(原文):Sponsor Decision
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-03-18
Fecal Microbiota Transplantation for Treatment of Gastrointestinal Dysbiosis or Clearance of ARO
编号:NCT03834051登记状态:提前终止企业 / 申办者:Vancouver Island Health Authority
药物 / 成分:Fecal Microbiota Transplantation
登记的停止原因(原文):Lack of funding
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-03-18
Effects of Intravenous GSK3858279 on a Battery of Evoked Pain Tests in Healthy Volunteers
编号:NCT04114656登记状态:提前终止企业 / 申办者:GlaxoSmithKline
药物 / 成分:Placebo、GSK3858279
登记的停止原因(原文):This study was terminated due to meeting protocol defined futility.
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-03-18
Naxitamab and GM-CSF in Combination With IT in Patients With High-Risk Neuroblastoma
编号:NCT04560166登记状态:提前终止企业 / 申办者:Y-mAbs Therapeutics
药物 / 成分:Naxitamab and GM-CSF in combination with irinotecan and temozolomide
登记的停止原因(原文):Due to business priorities
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-03-18
Postoperative Pain Control Following Renal Transplant
编号:NCT05044429登记状态:提前终止企业 / 申办者:George Washington University
药物 / 成分:Intravenous Lidocaine、Transversus abdominis plane (TAP) block、Quadratus Lumborum (QL) Block
登记的停止原因(原文):Lack of interest for continuing on by PI and issues with IRB
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-03-15
Statin and Angiotensin-converting Enzyme Inhibitor on Symptoms in Patients With SCAD
编号:NCT02008786登记状态:提前终止企业 / 申办者:Cardiology Research UBC
药物 / 成分:ramipril、rosuvastatin、placebo
登记的停止原因(原文):Slow enrollment
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-03-15
Multiple Rising Does Study (Subcutaneous Doses) of BI 655064 in Male and Female Patients With Chronic Primary Immune Thrombocytopenic Purpura (ITP).
编号:NCT02009761登记状态:提前终止企业 / 申办者:Boehringer Ingelheim
药物 / 成分:BI 655064
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-03-15
The Efficacy of Denosumab in Incomplete Patients Spinal Cord Injury
编号:NCT03029442登记状态:提前终止企业 / 申办者:James J. Peters Veterans Affairs Medical Center
药物 / 成分:Denosumab (Prolia)、Placebo (normal saline)
登记的停止原因(原文):Study ended early due to COVID-19
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-03-15
CAR-T Cells Therapy in Relapsed/Refractory Multiple Myeloma
编号:NCT03473496登记状态:提前终止企业 / 申办者:Zhujiang Hospital
药物 / 成分:CART therapy in Relapsed/Refractory multiple myeloma
登记的停止原因(原文):After CAR-T treatment, the benefit is not significant, and it is difficult to enroll.
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-03-15
A Pilot Study of Perioperative Nivolumab and Paricalcitol to Target the Microenvironment in Resectable Pancreatic Cancer
编号:NCT03519308登记状态:提前终止企业 / 申办者:Abramson Cancer Center at Penn Medicine
药物 / 成分:Nivolumab、Nab-Paclitaxel、Gemcitabine、Paricalcitol
登记的停止原因(原文):The accrual goal could not be met and the drug manufacturer pulled support
查看官方原始记录 ↗